A Phase 2 Study of Budoprutug in Subjects With Primary Membranous Nephropathy

Recruiting now · Phase 2

Conditions studied: Primary Membranous Nephropathy

In brief

To evaluate the safety and tolerability of three dose regimens of budoprutug in subjects with PMN

Key facts

Study ID

NCT07096843

Run by

Climb Bio, Inc.

People needed

45

Starts

2025-08-25

Expected to finish

2027-10-01

Last updated by the study team

2026-07-16

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Confirmed diagnosis of PMN with positive anti-PLA2R antibodies
• CD19+ B cell count ≥40 cells/μL
• UPCR ≥2.0 g/g
• eGFR ≥35 mL/min/1.73 m²
• Stable RAAS inhibitor therapy
• Blood pressure <150/90 mmHg at baseline
• Adequate hematologic, hepatic, and renal function
• Willing to use effective contraception (both sexes)
• Other inclusion criteria may apply

You may not qualify if…

• Secondary Membranous Nephropathy
• Rapidly progressive glomerulonephritis or other glomerulopathies
• Prior B cell-depleting therapy within 24 weeks
• Recent use of immunosuppressants
• Active or high-risk infections
• History of malignancy
• Pregnancy or breastfeeding
• Recent major surgery or hospitalization
• Other exclusion criteria may apply

Where it is running

• Climb Bio Investigative Site #604 — CABA, Argentina (enrolling)
• Climb Bio Investigative Site #105 — Orlando, Florida, United States (enrolling)
• Climb Bio Investigative Site #108 — Atlanta, Georgia, United States (enrolling)
• Climb Bio Investigative Site #106 — Indianapolis, Indiana, United States (enrolling)
• Climb Bio Investigative Site #901 — Tbilisi, Georgia (enrolling)
• Climb Bio Investigative Site #204 — Taichung, Taiwan (enrolling)
• Climb Bio Investigative Site# 202 — Taipei, Taiwan (enrolling)
• Climb Bio Investigative Site# 201 — Taipei, Taiwan (enrolling)
• Climb Bio Investigative Site #205 — Taipei, Taiwan (enrolling)
• Climb Bio Investigative Site# 203 — Taipei, Taiwan (enrolling)
• Climb Bio Investigative Site #803 — Ivano-Frankivsk, Ukraine (enrolling)
• Climb Bio Investigative Site# 801 — Kyiv, Ukraine (enrolling)
• Climb Bio Investigative Site #805 — Kyiv, Ukraine (enrolling)
• Climb Bio Investigative Site #804 — Rivne, Ukraine (enrolling)
• Climb Bio Investigative Site #802 — Ternopil, Ukraine (enrolling)
• Climb Bio Investigative Site #101 — Clifton Park, New York, United States (enrolling)
• Climb Bio Investigative Site #104 — Sherman, Texas, United States (enrolling)
• Climb Bio Investigative Site# 602 — Buenos Aires, Argentina (enrolling)
• Climb Bio Investigative Site# 603 — Buenos Aires, Argentina (enrolling)
• Climb Bio Investigative Site #601 — CABA, Argentina (enrolling)
• Climb Bio Investigative Site #110 — Denver, Colorado, United States (enrolling)
• Climb Bio Investigative Site #606 — Santa Fe, Argentina (enrolling)
• Climb Bio Investigative Site #502 — Belo Horizonte, Brazil (enrolling)
• Climb Bio Investigative Site #505 — Minas Gerais, Brazil (enrolling)
• Climb Bio Investigative Site #506 — Pernambuco, Brazil (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.